| |
Available U.S. Patents
The following U.S. Patents
are available for licensing from Wistar.
Patent numbers link to the Patent PDF
file. Tech ID numbers (where applicable)
link to technology and reagent summaries
on the Wistar site.
| Patent
No. |
Inventor |
Title |
Date
Issued |
Tech
ID |
7,022,820
|
R.
Kaufman |
Gene
Product Over Expressed in Cancer Cells
|
04/04/2006
|
KR0301
|
6,960,566
|
M. Blaszczyk-Thurin
|
Compositions
and Methods for Treatment of Cancer
|
11/1/2005
|
TM98001
|
| 6,852,706 |
E.
Heber-Katz |
Methods
and Compositions for Healing Heart
Wounds |
02/08/05 |
HKE96001 |
| 6,831,063 |
G.
Prendergas,t
Kai Ge |
Bridging
Integrator-2(Bin2) nucleic acid molecules
and proteins and uses therefor |
12/14/04
|
PG98002 |
| 6,828,147 |
D.
Santoli,
A. Cesano,
G. Rovera |
Method
of modifying cytotoxic cells and uses
thereof |
4/06/04 |
SD98003 |
| 6,716,425 |
D.
Santoli,
A. Cesano,
G. Rovera |
Method
for Preventing Cancer Recurrence |
04/06/04 |
SD9218 |
| 6,645,498 |
D.
Herlyn,
A. Linnenbach,
H. Koprowski
|
Soluble
Variants of Type I Membrane Proteins,
and Methods of Using Same |
11/11/03 |
LA9112 |
| 6,638,408 |
D.
Speicher |
A
Method and Device for Analysis of
Charged Molecules by Solution Isoelectric
Focusing |
10/28/03 |
SD99001 |
| 6,555,658 |
G. Trinchieri |
Antibodies to Natural Killer Stimulatory Factor |
04/29/03 |
TG8829 |
| 6,555,579 |
D.
Kritchevsky |
Methods
for Reducing Atherosclerotic Plaques |
4/29/03 |
KD98001 |
| 6,538,173 |
E.
Heber-Katz |
Compositions
and Methods for Wound Healing |
3/25/03 |
HKE96001 |
| 6,528,307 |
D.
Herlyn |
Cytolytic
T-cell Clones Against colorectal carcinoma
and Methods of Use Theerof |
3/4/03 |
HD97001 |
| 6,486,133 |
M.
Herlyn |
Methods
for Inducing Localized Vascular Development
and Enhancing the Repair of a Wound
in the Mammamian Dermis
|
11/26/02 |
HM96001 |
| 6,448,389 |
E.
Gonczol |
Novel
Human Cytomegalovirus DNA Constructs
and Uses Therefor |
9/10/2002 |
GE96001 |
| 6,410,238 |
G.
Prendergast |
Box-dependent Myc-interacting
Protein (Bin1) Compositions and
Uses Therefor |
6/25/02 |
PG95145 |
| 6,388,062 |
T.
Halazonetis |
Modified
p53 Tetramerization Domains Having
Hydrophobic Amino Acid Substitutions
|
5/14/02 |
HT98001 |
| 6,350,615 |
R. Kaufman |
Gene Product Over Expressed in Cancer Cells |
02/26/02 |
KR0301 |
| 6,307,035 |
F.
Rauscher |
BRCA1
Associated Polynucleotide (BAP-1)
and Uses Therefor
|
10/23/01 |
RF96001 |
| 6,300,478 |
G.
Trinchieri |
Antibodies
to Natural Killer Stimulatory Factor
|
10/9/01 |
TG8829 |
| 6,291,437 |
E.
Gonczol |
Methods
and Compositions for Preventing or
Retarding the Development of Atherosclerotic
Lesions
|
9/18/01 |
GE96002 |
| 6,287,571 |
H.
Ertl |
A
Replication-Defective Adenovirus Human
Type 5 Recombinant as a Vaccine Carrier |
9/11/01 |
EH94144 |
| 6,239,326
B1 |
C.
Howe |
SPARC-Deficient
Transgenic Mice |
5/29/01 |
HC95001 |
|
6,221,635 |
G.
Rovera,
S. Mukhopadhyay |
Method
for Solid-Phase Amplification of DNA
Using Multiarrays |
4/24/01 |
RG98001 |
| 6,168,923 |
G.
Trinchieri |
Compositions
and Methods for Use of Il-12 as an
Adjuvant |
10/02/01 |
TG8829 |
| 6,140,465 |
G.
Prendergast |
BAU,
a BIN1-Interacting Protein, and Uses
therefor |
10/31/00 |
PG96001 |
| 6,048,702 |
G.
Prendergast,
D. Sakamuro |
Murine
and Human Box-dependent Myc-interacting
Protein (Bin1) and Uses Thereof |
4/11/00 |
PG95145 |
| 6,086,876 |
G.
Trinchieri,
D. Griffin,
C. Karp,
M. Wysocka |
Methods
and Compositions for the Inhibition
of Interleukin-12 Production |
7/11/00 |
TG96001 |
| 6,072,034 |
R. Kaufman |
Gene Product over Expressed in Cancer Cells |
06/06/00 |
KR0301 |
| 6,022,538 |
D.
Santoli,
A. Cesano,
G. Rovera
|
Method
of Treating Malignacies |
2/08/00 |
SD9218 |
| 6,019,978 |
H.
Ertl |
A
Replication-Defective Adenovirus Human
Type 5 Recombinant as a Vaccine Carrier
|
2/01/00 |
EH94144 |
| 5,976,539 |
G.
Trinchieri |
Compositions
and Methods for Use of IL-12 as an
Adjuvant |
11/02/99 |
TG8829 |
| 5,958,753
|
G.
Prendergast |
Nucleic
Acid Sequences Encoding Bau, a Bin1
Interacting Protein, and Vectors and
Host Cells Containing Same |
9/28/99 |
PG96001
|
| 5,912,142 |
R. Kaufman |
Gene Product over Expressed in Cancer Cells |
06/15/99 |
KR0301 |
| 5,872,154
|
G.
Trinchieri,
J. Wilson,
Y. Yang |
Method
of reducing an immune response to
a recombinant adenovirus |
2/16/99 |
TG8829 |
| 5,854,069 |
D.
Herlyn |
GD2
anti-idiotypic antibodies and uses
thereof |
12/29/98 |
HD96001 |
| 5,847,083 |
T.Halazonetis |
Modified
p53 constructs and use therefor |
12/8/98 |
HT95001 |
| 5,820,856 |
D.
Santoli,
A. Cesano,
G. Rovera |
Use
of modified TALL-104 cells to treat
cancer and viral diseases |
10/13/98 |
SD9218 |
| 5,811,523 |
G.
Trinchieri |
Antibodies
to Natural Killer Stimulatory Factor |
09/22/98 |
TG8829 |
| 5,789,158 |
B.
Knowles,
D. Johnson,
J. Rothstein,
D. Solter |
Developmental
embryonic mouse cDNA libraries |
8/4/98 |
KB-9210 |
| 5,763,174 |
K.
Nishikura |
RNA
editing enzyme and methods of use
thereof |
6/9/98 |
NK9480 |
| 5,723,581 |
G. Prendergast,
D. Sakamuro |
Murine
and human box-dependent Myc-interacting
protein (BIN1) and uses therefor |
3/3/98 |
PG95145 |
| 5,723,127 |
G.
Trinchieri |
Compositions
and Methods for Use of IL-12 as an
Adjuvant |
03/03/98 |
TG8829 |
| 5,721,340 |
T.
Halazonetis |
p53
proteins with altered tetramerization
domains |
2/24/98 |
HT9436 |
| 5,702,702 |
D.
Santoli,
A. Cesano, G.Rovera |
Modified
cytotoxic TALL cell line and compositions
and methods for manufacture and use
thereof |
12/30/97 |
SD9218 |
| 5,698,202 |
H.
Ertl,
J. Wilson |
A
replication-defective adenovirus human
type 5 recombinant as a vaccine carrier |
12/16/97 |
EH94144 |
| 5,683,690 |
D.Santoli,
A. Cesano, G.Rovera |
Modified
cytotoxic TALL cell line and compositions
and methods for manufacture and use
therefor as therapeuric reagents for
cancer |
11/4/97 |
SD9218 |
| 5,677,428 |
K.
Nishikura |
RNA
editing enzyme and methods of use
therefor |
10/14/97 |
NK9480 |
| 5,648,467 |
G.
Trinchieri |
IL-12
protein |
07/15/97 |
TG8829 |
| 5,648,072 |
G.
Trinchieri |
Methods
of Inducing Gamma Interferon and Stimulating
Blood Cell Populations Using NKSF |
07/15/97 |
TG8829 |
| 5,643,778 |
K.
Nishikura |
RNA
editing enzyme and methods of use
therefor |
7/1/97 |
NK9480 |
| 5,633,142 |
M.
Herlyn,
J. Morris, F.Rauscher,
U. Rodeck |
WT1
monoclonal antibodies and methods
of use therefor |
5/27/97 |
HM9461
|
| 5,622,835 |
M.
Herlyn,
J. Morris,
F. Rauscher,
U. Rodeck |
WT1
monoclonal antobodies (as amended) |
4/22/97 |
HM9461
|
| 5,605,830 |
G.
Prendergast,
D. Sakamuro |
Murine
and human c-Myc interacting protein
and uses therefor |
02/25/97 |
PG95145 |
| 5,582,996 |
P.
Curtis |
Bifunctional
antibodies and method of preparing
same |
12/10/96 |
CP905 |
| 5,573,925 |
T.
Halazonetis |
p53
proteins with altered tetramerization
domains |
11/12/96 |
HT9436 |
| 5,571,515 |
G.
Trinchieri |
Compositions
and Methods for Use of IL-12 as an
Adjuvant |
11/05/96 |
TG8829 |
| 5,569,454 |
G.
Trinchieri |
Methods
of Treating Infection using NKSF |
10/29/96 |
TG8829 |
| 5,457,038 |
G.
Trinchieri |
Natural
Killer Stimulatory Factor |
10/10/95 |
TG8829 |
| 5,272,082 |
D.
Santoli,
A. Cesano, G.Rovera |
Cytotoxic
T-ALL cell lines and uses therefor
(as amended) |
12/21/93 |
SD9218 |
| 5,185,254 |
A.
Linnenbach |
Gene
family of tumor associated antigens |
02/09/93 |
LA8839 |
| 5,132,223 |
E.
Levine |
Process
and medium for cloning and long-term
serial cultivation of human endothelial
cells |
07/21/92 |
LE8349 |
| 5,053,224 |
D.
Herlyn,
E. DeFreitas,
H. Koprowski |
Induction
of antibody response to solid tumors
with anti-idiotype antibodies |
10/01/91 |
KH8340 |
| 4,994,387 |
E. Levine |
Process and Medium for Cloning and Long-Term Serial Cultivation of Human Endothelial Cells |
02/19/91 |
LE8349 |
For possible licensing
of Wistar Patent(s) please contact:
Meryle J. Melnicoff,
Ph.D.
Director, Business Development
The Wistar Institute
3601 Spruce Street
Philadelphia, PA 19104
Phone: (215) 898-0049
Fax: (215) 573-2456
melnicoff@wistar.org
|
|
